Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-22-012695)

NAMES OF REPORTING PERSONS

LINDEN CAPITAL L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☒ (b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Bermuda

Accession Number:: 0001193125-22-012695
Form Type:: 13G Filing
Publication Date:: 2022-01-19 19:00:00

Filed By:: Linden Capital L.p.
Company:: Revelation Biosciences Inc.
Filing Date:: 2022-01-20
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
LINDEN GP	744,661	744,661	744,661	5.4%
LINDEN ADVISORS	744,661	744,661	744,661	5.4%
SIU MIN WONG	795,382	795,382	795,382	5.8%

Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Revelation Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

76135L101

(CUSIP Number)

January 14, 2022

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on the Following Pages)

(Page 1 of 10 Pages)

Page 2 of 10

CUSIP No. 76135L101

Page 3 of 10

CUSIP No. 76135L101

Page 4 of 10

CUSIP No. 76135L101

Page 5 of 10

CUSIP No. 76135L101

Page 6 of 10

Item 1(a).

Name of Issuer:

Revelation Biosciences, Inc. (the Issuer).

Item 1(b).

Address of Issuers Principal Executive Offices:

4660 La Jolla Village Drive, Suite 100

San Diego, CA 92122

Item 2(a).

Name of Person Filing:

This Statement is filed on behalf of each of the following persons (collectively, the Reporting Persons)

Linden Capital L.P., a Bermuda limited partnership (Linden Capital);

ii)

Linden GP LLC, a Delaware limited liability company (Linden GP);

iii)

Linden Advisors LP, a Delaware limited partnership (Linden Advisors); and

iv)

Siu Min (Joe) Wong (Mr. Wong).

This Statement relates to Shares (as defined herein) held for the account of Linden Capital and one or more separately managed accounts (the Managed Accounts). Linden GP is the general partner of Linden Capital and, in such capacity, may be deemed to beneficially own the Shares held by Linden Capital. Linden Advisors is the investment manager of Linden Capital and trading advisor or investment advisor for the Managed Accounts. Mr. Wong is the principal owner and controlling person of Linden Advisors and Linden GP. In such capacities, Linden Advisors and Mr. Wong may each be deemed to beneficially own the Shares held by each of Linden Capital and the Managed Accounts.

Item 2(b).

Address of Principal Business Office or, if None, Residence:

The principal business address for Linden Capital is Victoria Place, 31 Victoria Street, Hamilton HM10, Bermuda. The principal business address for each of Linden Advisors, Linden GP and Mr. Wong is 590 Madison Avenue, 15th Floor, New York, New York 10022.

Item 2(c).

Citizenship:

Linden Capital is a Bermuda limited partnership.

ii)

Linden GP is a Delaware limited liability company.

iii)

Linden Advisors is a Delaware limited partnership.

iv)

Mr. Wong is a citizen of China (Hong Kong) and the United States.

Page 7 of 10

Item 2(d).

Title of Class of Securities

Common Stock, par value $0.001 per share (the Shares).

Item 2(e).

CUSIP Number: 76135L101

Item 3.

If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

This Item 3 is not applicable.

Item 4.

Ownership:

Item 4(a)

Amount Beneficially Owned:

As of January 14, 2022, each of Linden Advisors and Mr. Wong may be deemed the beneficial owner of 795,382 Shares. This 795,382 amount consists of 744,661 Shares held by Linden Capital and 50,721 Shares held by the Managed Accounts. As of January 14, 2022, each of Linden GP and Linden Capital may be deemed the beneficial owner of the 744,661 Shares held by Linden Capital. All of the Shares beneficially held by the Reporting Persons are Shares obtainable upon exercise of warrants.

Item 4(b)

Percent of Class:

As of January 14, 2022, each of Linden Advisors and Mr. Wong may be deemed the beneficial owner of approximately 5.8% of Shares outstanding, and each of Linden GP and Linden Capital may be deemed the beneficial owner of approximately 5.4% of Shares outstanding. These percentages are derived from the 12,944,213 Shares outstanding based on the Issuers Current Report on Form 8-K filed on January 14, 2022.

Item 4(c)

Number of Shares as to which such person has:

As of January 14, 2022:


Linden Capital and Linden GP:
(i) Sole power to vote or direct the vote:			0
(ii) Shared power to vote or direct the vote:			744,661
(iii) Sole power to dispose or direct the disposition of:			0
(iv) Shared power to dispose or direct the disposition of:			744,661
Linden Advisors and Mr. Wong:
(i) Sole power to vote or direct the vote:			0
(ii) Shared power to vote or direct the vote:			795,382
(iii) Sole power to dispose or direct the disposition of:			0
(iv) Shared power to dispose or direct the disposition of:			795,382

Page 8 of 10

Item 5.

Ownership of Five Percent or Less of a Class:

This Item 5 is not applicable.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person:

See disclosure in Items 2 and 4 hereof.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

See disclosure in Item 2 hereof.

Item 8.

Identification and Classification of Members of the Group:

See Exhibit A attached hereto.

Item 9.

Notice of Dissolution of Group:

This item 9 is not applicable.

Item 10.

Certification:

By signing below, the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Sec. 240.14a-11.

Item 11.

Materials to Be Filed as Exhibits:

Exhibit A: Joint Filing Statement

Page 9 of 10

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, I certify that the information with respect to it set forth in this statement is true, complete, and correct.

Dated: January 19, 2022


LINDEN CAPITAL L.P.

By:	Linden GP LLC, its general partner

	By:	/S/ Saul Ahn
		Saul Ahn,
		Authorized Signatory

LINDEN GP LLC

By:	/S/ Saul Ahn
	Saul Ahn,
	Authorized Signatory

LINDEN ADVISORS LP

By:	/S/ Saul Ahn
	Saul Ahn,
	General Counsel

SIU MIN WONG

By:	/S/ Saul Ahn
	Saul Ahn, Attorney-in-Fact for Siu Min Wong**

**	Duly authorized under Siu Min Wongs Power of Attorney, dated June 10, 2019, incorporated herein by reference to Exhibit B of the statement on Schedule 13G filed by Linden Capital L.P. on June 19, 2019 in respect of its holdings in Haymaker Acquisition Corp II.